Novel rhodium, iridium and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anti-cancer agents. The complexes show promising cytotoxicities, with the presence, position and number of halides having a significant effect on the corresponding IC50 value. A ruthenium complex is more cytotoxic than cisplatin on HT-29 cells and it remains active even under hypoxic conditions making it a promising candidate for in vivo studies.
Introduction
In recent years, organometallic ruthenium complexes have been well researched as anti-cancer agents. [1] [2] [3] [4] [5] Rhodium and iridium complexes, however, remain relatively unexplored. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We have previously reported an initial study demonstrating that half-sandwich ruthenium-arene picolinamide and quinaldamide complexes with an ancillary chloride ligand show promising activity as anti-cancer agents, whereby the more hydrophobic quinaldamide complexes are more active than their picolinamide analogues. 21 In collaboration with Sadler, we have also shown that osmium congeners have also shown potential as cytotoxic agents. 4 More recently, we reported a preliminary investigation into two iridium-Cp* chloride picolinamide complexes and their IC50 values for both HT-29 and MCF-7 cell lines. 16 In our continued study to optimise the design and potency of organometallic anti-cancer agents, we have extended our range of neutral complexes to include halide substituents on the phenyl ring for ruthenium para-cymene and rhodium-/iridium-Cp* in order to determine structure activity relationships. It is known that cancerous cells are in a hypoxic environment whereby the median oxygen partial pressure is approximately 10 mm Hg. 22 Many cytotoxic drugs are significantly less active when tested in vitro on cells in a hypoxic environment compared to normoxic conditions. 23 This is thought to be independent of the cell pathway of the drug and rather due to hypoxia-induced resistance. For this reason, the most active compound of the series under normoxic conditions has been tested on MCF-7 cells in hypoxic conditions.
Results and Discussion
Synthesis of Compounds Scheme 1 shows the synthesis of the group 9 complexes 1-12. The group 9 picolinamide complexes, 1-8,
were prepared using various methods depending on their identity. The iridium Cp* complexes, shown in Scheme 1a), were prepared either according to Method A in the cases of 1, 6 and 7 or Method B in the cases of 2-5. Complex 8 was prepared according to Scheme 1b). The ruthenium-para-cymene picolinamide complexes, 9-12, and quinaldamide complex, 13, were prepared according to Scheme 1c)
and Scheme 1d) respectively. In all cases the picolinamide/ quinaldamide ligand was deprotonated and bound through the nitrogen atoms to form a neutral 18 electron species. All complexes were characterized H} NMR spectroscopy, CHN analysis and mass spectrometry. In addition, crystal structures were obtained of compounds 3, 4 and 9-13.
13
Scheme 1 Synthesis of a) iridium-Cp*, b) rhodium-Cp*, c) ruthenium-para-cymene picolinamide complexes and d) a ruthenium-para-cymene quinaldamide complex X-ray Crystallographic Data Figure 1 shows the molecular structures of compounds 3, 4 and 9-13, with the general X-ray data shown in Table 1 and selected bond lengths and angles shown in Table 2 and Table 3 respectively. The iridium picolinamide complexes 3 and 4 were crystallized using layer diffusion with a dichloromethane/ hexane solvent system. The ruthenium picolinamide and quinaldamide complexes, 9 and 12 respectively, were recrystallised from a methanolic solution, complexes 11 and 12 from a deuterated methanolic solution and complex 10 from an acetone solution. All of the compounds exhibit a pseudo octahedral geometry about the metal centre, whereby the para-cymene/Cp*/Cp ‡ occupies 3 coordination sites and the angle between the centroid of the Cp*/Cp ‡ /para-cymene ring and the other coordinating atoms are between 125.9-135.1
degrees. The angle between the coordinated nitrogens and the metal centre is between 76.27 and 77.05
degrees. This is due to the rigidity of the picolinamide ligand. 
Experimental Details
The picolinamide ligands 24 were prepared according to the literature method. All other reagents are commercially available and were used as received. The crystal was then mounted onto a glass capillary and attached to a goniometer head on a Bruker X8
Apex diffractor using graphite monochromated Mo-K radiation ( = 0.71073 Å) and 1.0º -rotation frames. The crystal was then cooled to 150K by an Oxford cryostream low temperature device. 25 The full data set was recorded and the images processed using DENZO and SCALEPACK programs. 26 The structures were solved by Stephanie Lucas or Christopher Pask. Structure solution by direct methods was achieved through the use of SHELXS86 27 , SIR92 28 or SIR97 29 programs, and the structural model defined by full matrix least squares on F 2 using SHELX97. 27 Molecular graphics were plotted using ORTEP.
Editing of Crystallographic Information files and construction of tables of bond lengths and angles was achieved using WC 30 and PLATON. 31 Hydrogen atoms were placed using idealised geometric positions (with free rotation for methyl groups), allowed to move in a "riding model" along with the atoms to which they were attached, and refined isotropically.
Cell Line Testing
The in vitro tests were performed on HT-29 (human colon adenocarcinoma), A2780 (human ovarian carcinoma) and MCF-7 (human breast adenocarcinoma) cell lines. Cells were incubated in 96-well plates at a concentration of 2 × 10 4 cells cell/ml. β00 L of growth media (RPMI 1640 supplemented with 10%
foetal calf serum, sodium pyruvate (1 mM) and L-glutamine (2 mM)) was added to each well and the plates were incubated for 24 hours at 37 °C in an atmosphere of 5% CO2 prior to drug exposure. 
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